HDFC Fixed Maturity Plan new fund offer closes 9th November
HDFC Mutual Fund has launched HDFC FMP 36M October 2011 (1), a close-ended income scheme.
The investment objective of the scheme to generate income through investments in Debt / Money Market Instruments and Government Securities maturing on or before the maturity date of the respective Plan(s). The tenure of the scheme is 36 months.
The new fund offer closes on 9 November 2011. The minimum investment amount is Rs5000.
Crisil Short Term Bond Fund Index is the benchmark index. Bharat Pareek is the fund manager.
IT firm NIIT Technologies will invest up to Rs175 crore for the second phase of expansion of its campus in Greater Noida
IT firm NIIT Technologies will invest up to Rs175 crore for the second phase of expansion of its campus in Greater Noida. "The Phase-II expansion will begin in January next year and will have an investment of Rs165-175 crore. It will take about 6-8 months to get completed and would create a capacity of 4,000 people," a NIIT Technologies spokesperson said. At present, the campus has 3,000 employees and caters to mostly new business.
The company plans to complete the construction at the campus in three phases. When completed, it would have a capacity of close to 11,000 employees. The company has spent around Rs135 crore in the first phase of expansion.
NIIT Technologies focuses on industry verticals like banking and financial services, insurance, healthcare, travel, transportation and logistics, and retail and distribution. It has footprint across North America, Europe, Asia and Australia.
The company has four facilities in the Delhi-NCR region. Asked how the company would fund the expansion, the spokesperson said it would be done through internal accruals. "We have a very strong order book of $200 million of fresh order intake and a total of $232 million of executable order book over the next 12 months. The expansion is in line with the momentum we see in business," the spokesperson said.
In the late afternoon, NIIT was trading at around Rs229.95 per share on the Bombay Stock Exchange, 0.02% down from the previous close.
Lupin believes that it is one of the first applicants to file an ANDA for LoSeasonique® Tablets and will be entitled to 180 days of marketing exclusivity
Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin pharmaceuticals Inc. (LPI) has received final approval for its Levonorgestrel and Ethinyl Estradiol Tablets 0.1 mg /0.02 mg and Ethinyl Estradiol Tablets 0.01 mg from the U.S. Food and Drug Administration (FDA) for the company’s Abbreviated New Drug Application (ANDA) to market a generic version of Teva Women’s Health, Inc’s. LoSeasonique® Tablets.
Lupin believes that it is one of the first applicants to file an ANDA for LoSeasonique® Tablets and will be entitled to 180 days of marketing exclusivity.
Commenting on the launch, Nilesh Gupta, group president of Lupin said, “We are very happy to receive this approval. This product approval demonstrates our commitment to deliver a quality Oral Contraceptive pipeline to consumers in the U.S., built around our development and vertically integrated manufacturing strengths. Consumers can be assured they are receiving quality products that they have been accustomed to, at a more affordable price”.
In the late afternoon, Lupin was trading at around Rs470.05 per share on the Bombay Stock Exchange, 0.85% down from the previous close.